Learn how causal mechanism and effect analysis (CMEA) and its principles can be used to develop and maintain safer working environments in the pharma/biotech and medical device industries.
- In Bioprocessing, Trusted Data Is A Process Variable
- Are Biopharma Companies Outsourcing Their Ability To Think?
- Why Operational Readiness Is The Missing Piece In Biosimilar Adoption
- Demonstrating Non-Inferiority Of BFPCs Vs. Traditional Air Monitoring
- Exploring Takeda's Template For Sustainable Steam Generation
- Transforming Computer System Validation In The Life Sciences Industry
- Analyzing And Managing CDMO Project Risks Using Causal Mechanism & Effect Analysis
GUEST COLUMNISTS
-
In Bioprocessing, Trusted Data Is A Process Variable
As digital systems become increasingly interconnected, digital validation ensures systems generating and managing GxP data remain accurate, consistent, and trustworthy.
-
Are Biopharma Companies Outsourcing Their Ability To Think?
Amid gaining immediate access to external manufacturing capabilities, sponsor companies can lose the foundational understanding required to govern that capability.
-
Why Operational Readiness Is The Missing Piece In Biosimilar Adoption
Biosimilar success depends on seamless execution. Strong care coordination, patient education, and operational readiness are essential to improve access, adherence, and outcomes.
-
Demonstrating Non-Inferiority Of BFPCs Vs. Traditional Air Monitoring
Demonstrating non-inferiority of bio-fluorescent particle counter (BFPC) technology to traditional active air-sampling methods is essential for implementation. Here's how to approach it.
-
Exploring Takeda's Template For Sustainable Steam Generation
Takeda designed a model for delivering steam at 11 bar and up to 184 degrees using natural refrigerant and waste heat at one of its largest production sites.
-
Transforming Computer System Validation In The Life Sciences Industry
Regulators acknowledge how traditional CSV methods fail to meet modern demands for speed and flexibility. The scene is changing in favor of smarter, leaner validation.
-
Analyzing And Managing CDMO Project Risks Using Causal Mechanism & Effect Analysis
Since every sponsor–CDMO relationship can have widely different scopes, requirements, and procedures, this article focuses on the basic principles for analyzing and managing the risks of not achieving the relationship’s objectives.
BIOSIMILAR WHITE PAPERS
-
Assessing A Targeted Molecular Method Against Traditional In Vitro Testing For Adventitious Virus Detection
Discover a CHO AOF panel that provides rapid detection of relevant adventitious viral contaminants in bulk harvest material, and explore data showing equivalent sensitivity to the in vitro assay.
-
Economic Advantage Of Robotic Gloveless Pharmaceutical Isolators4/28/2025
Are robotic gloveless isolators the key to smarter, safer, scalable solutions? Discover how they can revolutionize aseptic filling by reducing contamination, minimizing waste, and enhancing manufacturing flexibility.
-
Unlocking The Full Potential Of Antibody-Drug Conjugates (ADCs)6/15/2026
ADCs are evolving rapidly. Gain insight into how success now hinges on managing complexity, delivery, and scalability to turn promising designs into viable therapeutic products.
-
A Comprehensive Solution For Adventitious Agent Testing2/13/2026
Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.
-
ADC Development Grows More Complex — SPR Insights Bring Clarity4/14/2026
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
Innovation In Filtration3/18/2025
Filtration removes contaminants to ensure safety and is essential in various applications, from lab-scale tasks to GMP production. Explore how its simplicity and reliability make it indispensable.
BIOSIMILAR APP NOTES & CASE STUDIES
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Henlius And Sandoz Enter Strategic Collaboration To Unlock Global Value Of Biosimilars Platform
- New Study From CVS Caremark And Employee Benefit News Shows How Employers Rely On Their Pharmacy Benefit Manager To Create Sustainable Pharmacy Solutions
- Mabwell Announces Strategic Partnerships For Aflibercept Biosimilar In Multiple ASEAN Countries
- Henlius Accelerates The New Landscape Of Breast Cancer Treatment As HANQUYOU Marks Six Years Since Its Approval
- Samsung Bioepis Launches OPUVIZ (Aflibercept) 40 mg/mL Pre-Filled Syringe Across Europe
- Amneal Completes Acquisition Of Kashiv BioSciences, Creating A Global Biosimilar Leader
- Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection For Its Denosumab Injections
- Kyungdong Pharmaceutical And Asimov Announce Completion Of Cell Line Development Campaign For Biosimilar Antibody
NEWSLETTER ARCHIVE
- 08.13.26 -- When Innovation Meets Scale
- 08.13.26 -- Managing CDMO Project Risks Using Causal Mechanism & Effect Analysis
- 08.06.26 -- Achieving Annex 1 Compliance In Sterile Manufacturing
- 07.30.26 -- FDA Explains How To Respond To Form 483 Observations
- 07.23.26 -- Solving Glycoengineering Challenges Could Begin At The Cell Line